参芪扶正注射液联合化疗治疗急性非淋巴细胞白血病的临床研究  

Clinical Study of Shenqifuzheng injection and Chemotherapy in DA Protocol in Treating Acute Nonlymphocytic Leukemia

作　　者：吴东红[1] 杨志刚[1] 李庆华[1] 

机构地区：[1]广东医学院附属医院血液内科,广东湛江524001

出　　处：《中国医疗前沿》2009年第5期3-4,共2页China Healthcare Innovation

摘　　要：目的比较参芪扶正注射液联合DA化疗方案或单纯DA方案治疗急性非淋巴细胞白血病(ANLL)的疗效及不良反应。方法入选的60例ANLL患者分为两组,观察组32例,采用参芪扶正注射液联合DA化疗方案治疗;对照组28例,单纯用DA方案治疗。观察两组缓解率、临床症状、不良反应等指标。结果观察组CR率为71.86%,明显高于对照组的53.57%(P<0.05);观察组总有效率(CR+PR)为93.72%明显高于对照组的71.43%(P<0.01)。两组临床症状改善率分别为75.00%和53.57%,两组比较有显著差异(P<0.05)。观察组神经毒性及心脏毒性的发生率明显低于对照组(P<0.01)。结论参芪扶正注射液联合DA化疗方案治疗急性非淋巴细胞白血病可起到减轻化疗的不良反应,提高治疗效果的作用。Objective To compare the efficacy and adverse reaction of chemotherapy in DA protocol alone or combined with Shenqifuzheng injection （SFI） for treatment of acute nonlymphocytic leukemia. Methods 60 patients were divided into 2 groups,the observed group（n=32）treated with DA plus SFI. And the control group （n=28）treated with DA alone. The remission rate, clinical symptom and adverse reaction of two groups were observed. Results In the treated group, CR rate was 71.86%, total effective rate was 93.72%; while in the control group, CR rate was 53.57%, total effective rate was 71.43%. Patients＇ improvement rate of clinical symptom in the treated group was improved more obviously than that in the control group （P〈0.05）, and the incidence rate of adverse reaction as neurotoxicity and cardiac toxicity were lower in the treated group than those in the control group （P〈0.01）. Conclusion Shenqifuzheng injection combined with DA protocol on acute nonlymphocytic leukemia can reduce the adverse reaction of chemotherapy and improve the therapeutic efficacy.

关 键 词：参茂扶正注射液 急性非淋巴细胞白血病 DA方案 治疗效果 

分 类 号：R730.52[医药卫生—肿瘤] R733.71[医药卫生—临床医学]